Anika Therapeutics Inc. Common Stock (ANIK)
Stock · NASDAQ · Health Care
$19.98as of 10/16/2026
Price chart
Active signals
ANIK Signal Track Record
How signals performed across all stocks →What ANIK's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 36 | +3.1% | 69% | October 7, 2026 |
| Bollinger Band Breakout | 26 | -0.2% | 46% | July 30, 2026 |
| Bollinger Band Breakdown | 21 | +3.4% | 71% | September 23, 2026 |
| 200-Day Moving Average TouchActive now | 10 | +2.3% | 60% | February 9, 2026 |
| Any 20-session window (baseline) | +0.5% | 53% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About ANIK
Anika Therapeutics, Inc., a joint preservation company, focuses on early intervention orthopedics in the United States, Europe, and internationally. The company offers osteoarthritis (OA) pain management products and services, such as Monovisc and Orthovisc, which are single- and multi-injection, HA viscosupplement products indicated for pain relief from OA conditions, as well as Cingal, a non-opioid, single-injectio…
- Sector
- Health Care
- Industry
- Medical/Dental Instruments
- Employees
- 235
- Website
- anika.com/
Fundamentals
- 1-day range
- $19.33$20.69
- Market cap
- $269.80M
- P/E (trailing)
- —
- P/E (forward)
- 21.55
- EPS (trailing)
- $-0.27
- Dividend yield
- —
- Beta
- 0.23
- Avg. volume
- 100.4K
How Anika Therapeutics Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Mar 3, 2026 · via SEC EDGAR / Finnhub
Forecasts
2 analyst ratings
Anika Therapeutics Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- ANIKAnika Therapeutics Inc. Common Stock$19.98▼ 3.43%Market cap $269.80MP/E —$8.67$22.88
- OSUROraSure Technologies Inc. Common Stock$3.61▼ 5.25%Market cap $275.39MP/E —$2.08$4.58
- TMCITreace Medical Concepts Inc. Common Stock$3.87▼ 6.07%Market cap $284.14MP/E —$1.17$7.08
- DRTSWAlpha Tau Medical Ltd. Warrant$2.68▼ 10.37%Market cap $284.27MP/E —$0.2725$4.62
- PROFProfound Medical Corp. Common Stock$6.01▼ 4.75%Market cap $288.52MP/E —$6.52$12.4
- INFUInfuSystems Holdings Inc. Common Stock$13.4▼ 3.74%Market cap $236.42MP/E 31.71$7.29$13.85
- SENSSenseonics Holdings Inc. Common Stock$7.77▼ 5.59%Market cap $215.29MP/E —$4.79$10.64
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| ANIK Anika Therapeutics Inc. Common Stock | $269.80M | — | $19.98 | ▼ 3.43% | $8.67$22.88 |
| OSUR OraSure Technologies Inc. Common Stock | $275.39M | — | $3.61 | ▼ 5.25% | $2.08$4.58 |
| TMCI Treace Medical Concepts Inc. Common Stock | $284.14M | — | $3.87 | ▼ 6.07% | $1.17$7.08 |
| DRTSW Alpha Tau Medical Ltd. Warrant | $284.27M | — | $2.68 | ▼ 10.37% | $0.2725$4.62 |
| PROF Profound Medical Corp. Common Stock | $288.52M | — | $6.01 | ▼ 4.75% | $6.52$12.4 |
| INFU InfuSystems Holdings Inc. Common Stock | $236.42M | 31.71 | $13.4 | ▼ 3.74% | $7.29$13.85 |
| SENS Senseonics Holdings Inc. Common Stock | $215.29M | — | $7.77 | ▼ 5.59% | $4.79$10.64 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Merck's Remigromig Meets Main Goal in Diabetic Macular Edema StudyYahoo · 9/25/2026
- Is Anika Therapeutics (ANIK) Outperforming Other Medical Stocks This Year?Yahoo · 9/25/2026
- AMGN's Dazodalibep Meets Goal in Systemic Sjogren's Disease StudyYahoo · 9/23/2026
- NVS Gets Positive CHMP Opinion for Cosentyx for Another IndicationYahoo · 9/21/2026
- PBYI's Alisertib Combo Phase II Study in Small Cell Lung Cancer BeginsYahoo · 9/18/2026
- B. Riley Securities Assumes Anika Therapeutics at Buy, Raises Price Target to $23Benzinga · 9/18/2026
- RCKT Aligns With FDA on Completing Phase II Study in Danon DiseaseYahoo · 9/16/2026
- Immunocore Hits Enrollment Target in Kimmtrak Label Expansion StudyYahoo · 9/15/2026
Insider Activity
Insider Actions →- Fischetti Gary P · August 4, 2026 · Buy1.0K @ $20.32
- Fischetti Gary P · August 3, 2026 · Buy1.0K @ $20.75
- Fischetti Gary P · June 18, 2026 · Grant10.4K
- Richard Stephen · June 18, 2026 · Grant10.4K
- Joseph H. Capper · June 18, 2026 · Grant10.4K
- Sheryl L. Conley · June 18, 2026 · Grant10.4K
- John B. Henneman III · June 18, 2026 · Grant10.4K
- Griffin Stephen D. · June 3, 2026 · Option Exercise12.8K
- Griffin Stephen D. · June 3, 2026 · Tax Withholding3.8K @ $14.41
- John B. Henneman III · May 1, 2026 · Buy5.0K @ $14.66
- Griffin Stephen D. · April 30, 2026 · Buy12.2K @ $12.29
Institutional Ownership
March 31, 2026
- Total shares held
- 12.17M
- Total value held
- $167.28M
- Institutional holders
- 125
- Unknown1.59M
- Unknown1.44M
- Unknown872.1K
- Unknown606.5K
- Unknown605.8K
- Unknown529.5K
- Unknown502.2K
- Unknown458.8K
- Unknown447.7K
- Unknown353.2K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
ANIK Stock Moves Amid Broader Biotech Sector News
Recent news coverage focuses on clinical trial results from other biotech companies like Merck and Amgen, rather than specific new developments for Anika Therapeutics. One article examines whether ANIK is outperforming other medical stocks this year. The stock currently trades within its 52-week range, with analysts maintaining a target price of $21.00.
ANIK Stock Moves Amid Broader Biotech Sector News. Recent news coverage focuses on clinical trial results from other biotech companies like Merck and Amgen, rather than specific new developments for Anika Therapeutics. One article examines whether ANIK is outperforming other medical stocks this year. The stock currently trades within its 52-week range, with analysts maintaining a target price of $21.00.